Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK/PD of EXS21546 in Healthy Males
NCT04727138Phase 1Completed
- Sponsor
- Exscientia
- Start
- Dec 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EXS-21546 in solid tumor (advanced stage), renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Exscientia. Primary endpoints: Treatment Emergent Adverse Events at 1 month, Area Under the Curve at 17 days and 1 more. Started Dec 2020; status: completed.
02
Drugs
EXS-21546
03
Conditions
solid tumor (advanced stage)renal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04727138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727138.